U.S. prosecutors are targeting generic pharma companies in a criminal investigation of suspected price collusion, according to a Bloomberg article.
The two-year antitrust investigation includes more than a dozen companies and about two dozen drugs, according to sources. The grand jury probe is examining whether some executives conspired to raise prices, and the first charges could come by the end of the year, the article said.
Major drugmakers receiving subpoenas include Mylan NV and Teva Pharmaceutical Industries. Other companies include Actavis, Lannett Co., Impax Laboratories Inc., Covis Pharma Holdings Sarl, Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo International Plc’s subsidiary Par Pharmaceutical Holdings and Taro Pharmaceutical Industries Ltd.
Read the Bloomberg story